Form 4: Monopar Therapeutics CEO Chandler Robinson Acquires Shares Through Vesting of Restricted Stock Units
SEC Form 4 Filing
Monopar Therapeutics CEO Chandler Robinson acquired shares through the vesting of restricted stock units, while also having shares withheld for tax purposes.
Summary
- Chandler Robinson, CEO of Monopar Therapeutics, acquired 4,895 shares of common stock on December 31, 2024, through the vesting of restricted stock units.
- Additionally, 2,209 shares were withheld by the company to cover taxes related to the vesting of these units.
- Following these transactions, Robinson directly owns 58,848 shares of Monopar Therapeutics common stock.
- Robinson also has indirect beneficial ownership of 855,589 shares through his role as a manager of Tactic Pharma LLC, although he disclaims beneficial ownership except to the extent of his pecuniary interest.
- The restricted stock units were granted in three tranches on January 26, 2021, February 2, 2022, and February 1, 2023, and vest quarterly.
Sentiment
Score: 6
Explanation: The document reflects a routine transaction related to executive compensation. It is neither particularly positive nor negative, but rather an expected event.
Positives
- The vesting of restricted stock units indicates that performance milestones have been met.
- The CEO's increased direct ownership aligns his interests with those of shareholders.
Risks
- The sale of shares to cover taxes could put downward pressure on the stock price.
Industry Context
This is a standard SEC Form 4 filing, which is common for publicly traded companies when insiders make transactions in their company's stock. It is a routine disclosure and does not indicate any unusual activity.
Comparison to Industry Standards
- The vesting of restricted stock units is a common form of executive compensation in the biotechnology industry.
- The tax withholding of shares is also a standard practice to cover tax liabilities associated with vesting.
Stakeholder Impact
- The vesting of restricted stock units may have a minor positive impact on employee morale.
- The sale of shares to cover taxes could have a minor negative impact on the share price.
Key Dates
| Date | Description |
|---|---|
| 01/26/2021 | Grant date of 12,612 restricted stock units, vesting quarterly until December 31, 2024. |
| 02/02/2022 | Grant date of 31,905 restricted stock units, vesting quarterly until December 31, 2025. |
| 02/01/2023 | Grant date of 33,803 restricted stock units, vesting quarterly until December 31, 2026. |
| 12/31/2024 | Date of the reported transactions: vesting of restricted stock units and tax withholding. |
| 01/02/2025 | Date the SEC Form 4 was signed. |
Keywords
Monopar Therapeutics, Chandler Robinson, restricted stock units, share vesting, insider trading, SEC Form 4, MNPR, Tactic Pharma LLC
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.